Anales de la RANM

14 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 AGONISTAS DEL RECEPTOR GLP-1 EN OBESIDAD Escalada J An RANM. 2026;143(01): 12 - 14 BIBLIOGRAFÍA 1. Drucker DJ. The expanding landscape of GLP- 1 medicines. Nat Med. 2026 ;32(1):47-57. doi: 10.1038/s41591-025-04124-5. Epub 2026 Jan 2. PMID: 41482564. 2. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-ge- neration incretin-based medications: metabo- lic, cardiovascular, and renal benefits. Lancet. 2026;S0140-6736(25)02105-1. doi: 10.1016/ S0140-6736(25)02105-1. Epub ahead of print. PMID: 41547366. 3. Webster CM, Mittal N, Dhurandhar EJ, Dhurand- har NV. Potential contributors to variation in weight-loss response to liraglutide. Obes Rev. 2023;24(7):e13568. doi: 10.1111/obr.13568. Epub 2023 Apr 17. PMID: 37069131. 4. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi: 10.1111/dom.70141. Epub 2025 Oct 9. PMID: 41068996; PMCID: PMC12673431. 5. Kushner RF, Almandoz JP, Rubino DM. Managing Adverse Effects of Incretin-Based Medications for Obesity. JAMA. 2025;334(9):822-823. doi: 10.1001/jama.2025.11153. PMID: 40728833. 6. Ballesteros-Pomar MD, Bretón I. Adverse effects and other aspects of drugs with incretin effect. Med Clin (Barc). 2025;165(2):107041. 7. Yabut JM, Drucker DJ. Glucagon-like peptide-1 medicines and cancer. Nat Cancer. 2026 Jan 16. doi: 10.1038/s43018-025-01110-1. Epub ahead of print. PMID: 41545715. 8. Hidalgo Ramos RA, Ortiz M, Dufner Krieger S, Secades D. Semaglutide and Non-arteritic An- terior Ischemic Optic Neuropathy: A System- atic Review. Cureus. 2025;17(8):e89656. doi: 10.7759/cureus.89656. PMID: 40926946; PMCID: PMC12415119. 9. Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and Nutritional Deficiencies Asso- ciated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026;16(1):e70070. doi: 10.1111/cob.70070. PMID: 41549912. 10. Tzang CC, Wu PH, Luo CA, et al. Metabolic re- bound after GLP-1 receptor agonist discontinu- ation: a systematic review and meta-analysis. EClinicalMedicine. 2025 Nov 28;90:103680. doi: 10.1016/j.eclinm.2025.103680. PMID: 41399474; PMCID: PMC12702299. 11. Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indi- cations of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026;335(5):434-438. Si desea citar nuestro artículo: Escalada J. Agonistas del receptor GLP-1 (y sus variantes) en obesi- dad: entre la innovación terapéutica y la responsabilidad clínica. An RANM. 2026;143(01): 12– 14. DOI: 10.32440/ar.2026.143.01. ed01